ETHZilla

ETHZilla DSCR

The Debt Service Coverage Ratio (DSCR) of ETHZilla (ETHZ) as of Nov 20, 2026 is -100.77. In the previous year, Debt Service Coverage Ratio (DSCR) was -9.58 — a change of 951.58% (lower).

DSCR

-100.77

YoY

951.58%

Last updated:

Debt Service Coverage Ratio (DSCR) of ETHZilla is 2025 -100.77 . Debt Service Coverage Ratio (DSCR) of ETHZilla was 2024 -9.58 . It decreases by 951.58% lower compared to the previous year.

The ETHZilla DSCR history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

DSCR
Date
DSCR
Jan 1, 2016
0.00 USD
Jan 1, 2018
-2.14 USD
Jan 1, 2019
-0.94 USD
Jan 1, 2021
-9.90 USD
Jan 1, 2022
-9.05 USD
Jan 1, 2023
-10.36 USD
Jan 1, 2024
-9.58 USD
Jan 1, 2025
-100.77 USD
The ETHZilla DSCR history
YEARDSCRYoY
-100.77+951.58%
-9.58-7.52%
-10.36+14.47%
-9.05-8.52%
-9.90+952.11%
-0.94-56.02%
-2.14—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ETHZilla Stock analysis

What does ETHZilla do? 180 Life Sciences Corp. develops pharmaceuticals for chronic pain and inflammatory diseases, focusing on three research programs: Fibrosis and Anti-TNF, SCAs, and a7nAChR. The Fibrosis and Anti-TNF program targets conditions such as Dupuytren’s contracture, frozen shoulder, polycystic ovarian disease (POCD), and nonalcoholic steatohepatitis (NASH). The SCAs program addresses chronic pain and early arthritis, while the a7nAChR program focuses on smoking cessation and ulcerative colitis. The company generates revenue through the development and potential future sale of these pharmaceutical products, targeting patients and healthcare providers in the treatment of inflammatory and chronic pain conditions. The company operates as a research and development firm with a pipeline of drugs in separate areas of inflammation. Its products are designed to treat specific diseases within inflammation, including Dupuytren’s contracture, frozen shoulder, POCD, NASH, chronic pain, early arthritis, and ulcerative colitis. Revenue is derived from the commercialization of these pharmaceuticals once they reach the market, with no mention of current sales or partnerships in the business description. 180 Life Sciences Corp. is structured around three distinct drug development programs, each targeting a specific disease area. The Fibrosis and Anti-TNF program covers multiple inflammatory conditions, while SCAs and a7nAChR address chronic pain and smoking-related health issues, respectively. The company’s revenue model relies on the successful development and market entry of these pharmaceuticals, with no indication of current revenue streams beyond its R&D phase. ETHZilla is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ETHZilla stock

Debt Service Coverage Ratio (DSCR) of ETHZilla is -100.77 in 2025.

Debt Service Coverage Ratio (DSCR) of ETHZilla changed from -9.58 to -100.77, representing a 951.58% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Service Coverage Ratio (DSCR) ETHZilla since 2006 – with annual values, charts, and detailed analysis.

The DSCR measures a company's ability to service its debt obligations from operating income. A ratio above 1.0 indicates sufficient income to cover debt payments.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt Service Coverage Ratio (DSCR)'s ETHZilla with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — ETHZilla

All Key Metrics — ETHZilla